Recent News

• 11.19.2025 - Soligenix Achieves Enrollment Milestone for Planned Interim Analysis in Confirmatory Phase 3 Clinical Trial of HyBryte™ for the Treatment of Cutaneous T-Cell Lymphoma
• 11.07.2025 - Soligenix Announces Recent Accomplishments and Third Quarter 2025 Financial Results
• 09.29.2025 - Soligenix Announces Closing of $7.5 Million Public Offering
• 09.26.2025 - Soligenix Announces Pricing of $7.5 Million Public Offering
• 09.23.2025 - Soligenix Announces Appointment of Former White House Economic Adviser Tomas J. Philipson, PhD as Strategic Advisor
• 09.04.2025 - Soligenix Announces Publication Describing Long-Term High Temperature Stability of Protein Subunit Vaccines for Ebola and Related Viruses
• 09.02.2025 - Soligenix Invited to Present at the H.C. Wainwright 27th Annual Global Investment Conference

Recent Filings

• 11.18.2025 - 8-K Current report
• 11.14.2025 - SCHEDULE 13G Statement of Beneficial Ownership by Certain Investors
• 11.07.2025 - 424B3 Prospectus [Rule 424(b)(3)]
• 11.07.2025 - 424B3 Prospectus [Rule 424(b)(3)]
• 11.07.2025 - 424B3 Prospectus [Rule 424(b)(3)]
• 11.07.2025 - 10-Q Quarterly report [Sections 13 or 15(d)]
• 10.03.2025 - 4 Statement of changes in beneficial ownership of securities
• 10.01.2025 - SCHEDULE 13G Statement of Beneficial Ownership by Certain Investors
• 09.29.2025 - EX-99.1 EX-99.1
• 09.29.2025 - 8-K Current report